Use of pentoxifylline therapy for patients with aids-related wasting: Pilot study

Clinical Infectious Diseases

Volumn 18, Issue 1, 1994, Pages 97-99

  Landman, David ^a   Sarai, Abey ^a   Sathe, Sadhana S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; PENTOXIFYLLINE; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE;

ADULT; AIDS RELATED COMPLEX; CACHEXIA; CLINICAL ARTICLE; DRUG USE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MUSCLE ATROPHY; NOTE; PRIORITY JOURNAL; WEIGHT GAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; CACHEXIA; HUMAN; MALE; MIDDLE AGE; PENTOXIFYLLINE; PILOT PROJECTS; PROGNOSIS; TUMOR NECROSIS FACTOR; WEIGHT LOSS;

EID: 0028089362     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/clinids/18.1.97     Document Type: Article

References (25)

1. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444-7.
2. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF-a/cachectin induce cachexia in mice. Cell 1987;50:555-63.
3. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin I for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991:51:415-21.
4. Han J, Thompson P, Beutler B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. Exp Med 1990;172:391-4.
5. Dezube BJ, Fridovich-Kei JL, Bouvard I, Lange RF, Pardee AB. Pentoxifylline and wellbeing in patients with cancer [letter]. Lancet 1990:335:662.
6. Langstein HN, Doherty GM, Fraker DL, Buresh CM, Norton JA. The roles of gamma-interferon and tumor necrosis factor alpha in an experimental rat model of cancer cachexia. Cancer Res 1991:51: 2302-6.
7. Grunfeld C, Wilking H, Neese R, et al. Persistence of the hypertriglycer- idemic effect of tumor necrosis factor despite development of tachyphylaxis to its anorectic/cachectic effects in rats. Cancer Res 1989:49:2554-60.
8. Darling G, Fraker DL, Jensen JC, Gorschboth CM, Norton JA. Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res 1990:50:4008-13.
9. Hober D, Haque A, Wattre P, Beaucaire G, Mouton Y, Capron A. Production of tumour necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-I) in patients with AIDS: enhanced level ofTNF-alpha is related to a higher cytotoxic activity. Clin Exp Immunol 1989:78:329-33.
10. Lahdevirta J, Maury CP, Teppo AM, Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med 1988:85:289-91.
11. Kobayashi S, Hamamoto Y, Kobayashi N, Yamamoto N. Serum level of TNF alpha in HIV-infected individuals [letter], AIDS 1990:4:169-70.
12. Noronha IL, Daniel V, Schimpf K, Opelz G. Soluble IL-2 receptor and tumor necrosis factor-alpha in plasma of haemophilia patients infected with HIV. Clin Exp Immunol 1992:87:287-92.
13. Von Sydow M, Sonnerborg A, Gaines H, Slranncgard O. Lnterferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HI V-1 infection. AIDSResHum Retroviruses 1991:7:375-80.
14. Ayehunie S, Sonnerborg A, Yemane-Berhan T, Zewdie DW, Britton S, Strannegard O. Raised levels of tumour necrosis lactor-alpha and neopterin, but not inlerferon-alpha, in serum of HiV-l-infected patients from Ethiopia. Clin Lxp Immunol 1993:91:37-42.
15. Ammann AJ, Palladino MA, Voiberding P, Abrams D, Martin N, Conant M. Fumor necrosis factors alpha and beta in acquired immunodeficiency svndrome and AIDS-related complex. L Clin Immunol 1987:7:481-5.
16. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating inlerferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency svndrome. Am J Med 1991:90:154-62.
17. Reddy MM, Sorrell SI, Lange M, Grieco MH. I umor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations. I Acquir Immune Delic Syndr 1988;1:436-40.
18. Hommes MJ, Romijn JA, Codified MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men Metabolism 1990:39:1186-90.
19. Dezube BJ, Pardee AB, Chapman B, et al. Pentoxifylline (I rental) decreases tumor necrosis factor (TNF-a) and HIV replication in patients with AIDS (abstract MoB 0019), In: Program and abstracts of the VIII International Conference on AIDS Amsterdam. Congrev Holland B.V. 1992.
20. Dezube BJ, Pardee AB, Chapman B, et al. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic Syndr 1993;6:787-94.
21. Nelson S, Bagbv GJ, Summer WR. Alcohol-induced suppression of tumor necrosis factor: a potential risk factor lor secondary infection in the acquired immunodeficiency' svndrome Prog Clin Biol Res 1990:325:211-20.
22. Mellors JW, Griffith BP, Ortiz MA, Landry ML, Rvan JL. Tumor necrosis factor-alpha/cachectin enhances human immunodeficiency virus type I replication in primary macrophages. J Infect Lfis 1991:163:78-82.
23. Ito M, Baba M, Mori S, et al. Tumor necrosis factor antagonizes inhibitory effect of azidothymidine on human immunodeficiency virus replication in vitro. Biochcm Biophys Res Commun 1990:166:1095-101.
24. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type I in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991:77:1653-6.
25. Dezube BJ, Eder JP, Pardee AB. Phase I trial of escalating pentoxifylline dose with constant dose thiotepa. Cancer Res 1990:50:6806-10